Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes - Cavo, A; Rubagotti, A; Zanardi, E (Therapeutic advances in medical oncology, 2018)
et al.